News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Eribulin + HP as first-line treatment of locally advanced/metastatic HER2+ breast cancer
Breast Cancer
Jan 12, 2025, 08:51

Eribulin + HP as first-line treatment of locally advanced/metastatic HER2+ breast cancer

Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X:

“Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial

The results suggested that eribulin + HP is an option for first-line treatment of locally advanced/metastatic HER2+ BC.”

Eribulin + HP as first-line treatment of locally advanced/metastatic HER2+ breast cancer

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial | Journal of Clinical Oncology

Authors: Toshinari Yamashita, Shigehira Saji, Toshimi Takano, Yoichi Naito, Michiko Tsuneizumi, Akiyo Yoshimura, Masato Takahashi, Junji Tsurutani, Tsuguo Iwatani, Masahiro Kitada, Hiroshi Tada,  Natsuko Mori, Toru Higuchi, Tsutomu Iwasa, Kazuhiro Araki, Kei Koizumi,  Hiroki Hasegawa, Yohei Uchida, Satoshi Morita, Norikazu Masuda.

Eribulin + HP as first-line treatment of locally advanced/metastatic HER2+ breast cancer

Akiyo Yoshimura cancer Elisabetta Bonzano Hiroki Hasegawa Hiroshi Tada Junji Tsurutani Kazuhiro Araki Kei Koizumi Masahiro Kitada Masato Takahashi Michiko Tsuneizumi Natsuko Mori Norikazu Masuda OncoDaily Oncology Satoshi Morita Shigehira Saji Toru Higuchi Toshimi Takano Toshinari Yamashita Tsuguo Iwatani Tsutomu Iwasa Yohei Uchida Yoichi Naito
Special Coverage
Blog
May 30, 2025, 01:27
$225,000 AACR Gertrude B. Elion Award Supports Junior Faculty Cancer Research - AACR
Blog
May 30, 2025, 01:15
Lung cancer is now the leading cause of cancer death among women worldwide - UICC
Blog
May 30, 2025, 01:04
Monica Kraft: New Evidence Supports As-Needed Albuterol and Budesonide for Mild Asthma
Blog
May 30, 2025, 00:42
Advocating for Better Brain Cancer Care in Regional NSW - Mark Hughes Foundation Centre for Brain Cancer Research
Blog
May 30, 2025, 00:25
Jérôme Salomon: Countries Agree to Update Global Action Plan to Reduce Deaths from Antimicrobial Resistance
Blog
May 29, 2025, 23:20
Alvaro Lassalet: Honored to Join as Associate Editor for Neuro-oncology Pediatrics Journal
Blog
May 29, 2025, 22:49
European Liver Patients'​ Association: The Role of Research and Innovation in Advancing Liver Cancer Therapies
Opinion
May 29, 2025, 22:38
Prerana Jha on ctDNA Molecular Profiling in Indian Lung Cancer Patients Study
Blog
May 29, 2025, 22:33
Ash Tewari Discusses Prostate Cancer Risk and Screening Guidelines - Mount Sinai Department of Medicine
Insight
May 29, 2025, 22:26
Alberto Puccini Shared Insights from AACR 2025 Update at Bari Congress
Blog
May 29, 2025, 22:19
Wafaa M Rashed Highlights PAPERI Blog on Prenatal Genetic Testing Policy in Africa by Mutaz Mohammed
Opinion
May 29, 2025, 22:12
ELPA Highlight Liver Cancer Awareness and Prevention During European Week Against Cancer